Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine
Frontiers in Pharmacology · 13.03.2024 · 15
DOI: 10.3389/fphar.2024.1348112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.03.2024. Verfasst von Winnie S Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Net/Bio Inc, Los Angeles, CA, United States. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In recent years, the development of sensor and wearable technologies have led to their increased adoption in clinical and health monitoring settings. One area that is in early, but promising, stages of development is the use of biosensors for therapeutic drug monitoring (TDM). Traditionally, TDM could only be performed in certified laboratories and was used in specific scenarios to optimize drug dosage based on measurement of plasma/blood drug concentrations. Although TDM has been typically pursued in settings involving medications that are challenging to manage, the basic approach is useful for characterizing drug activity. TDM is based on the idea that there is likely a clear relationship between plasma/blood drug concentration (or concentration in other matrices) and clinical efficacy. However, these relationships may vary across individuals and may be affected by genetic factors, comorbidities, lifestyle, and diet. TDM technologies will be valuable for enabling precision medicine strategies to determine the clinical efficacy of drugs in individuals, as well as optimizing personalized dosing, especially since therapeutic windows may vary inter-individually. In this mini-review, we discuss emerging TDM technologies and their applications, and factors that influence TDM including drug interactions, polypharmacy, and supplement use. We also discuss how using TDM within single subject (N-of-1) and aggregated N-of-1 clinical trial designs provides opportunities to better capture drug response and activity at the individual level. Individualized TDM solutions have the potential to help optimize treatment selection and dosing regimens so that the right drug and right dose may be matched to the right person and in the right context.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Net/Bio Inc, Los Angeles, CA, United States.
- Translational Genomics Research Institute (TGen), Phoenix, AZ, United States.
- University of Chicago, Chicago, IL, United States.
- Stanford University, Stanford, CA, United States.
Zitieren
APA
Liang, W. S., Beaulieu-Jones, B., Smalley, S., Snyder, M., Goetz, L. H., & Schork, N. J. (2024). Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1348112
Vancouver
Liang WS, Beaulieu-Jones B, Smalley S, Snyder M, Goetz LH, Schork NJ. Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1348112
BibTeX
@article{Liang2024,
author = {Liang, Winnie S and Beaulieu-Jones, Brett and Smalley, Susan and Snyder, Michael and Goetz, Laura H and Schork, Nicholas J},
title = {Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1348112}
}
EUVIMED